In vitro experiments demonstrated that dasatinib, a Src inhibitor, promoted M2-like macrophages to polarize toward M1-like macrophages in cisplatin-resistant lung cancer cell lines A549R and H460R by modulating the Src/CD155/MIF axis and reducing the expression of the stem cell markers Notch1 and β-catenin. Here, SRC is linked to lung carcinoma.